ROCKVILLE - REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a live webcast to discuss new interim clinical data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 for the treatment of Duchenne muscular dystrophy.

Primary investigator Aravindhan Veerapandiyan, M.D. will join the webcast and be available for Q&A.

Webcast details

Title: Interim Clinical Data from Phase I/II AFFINITY DUCHENNE Trial of RGX-202

Date/Time: Tuesday, March 5, 2024, at 8:30 a.m. EST

Access: The live webcast can be accessed in the Investors section of REGENXBIO's website at WWW.REGENXBIO.COM. An archived replay of the webcast will be available for approximately 30 days following the presentation.

Muscular Dystrophy Association Clinical & Scientific Conference presentation details

Title: RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy: Interim clinical data

Session: Clinical Trial Updates

Date/Time: Wednesday, March 6, 2024, 12:00 p.m. EST

Presenter: Aravindhan Veerapandiyan, M.D., Director of the Comprehensive Neuromuscular Program, PPMD Certified Duchenne Care Center, and Co-Director of the Muscular Dystrophy Association Care Center at Arkansas Children's Hospital

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.

Contacts:

Dana Cormack

Email: DCORMACK@REGENXBIO.COM

Chris Brinzey

Tel: 339-970-2843

Email: CHRIS.BRINZEY@WESTWICKE.COM

(C) 2024 Electronic News Publishing, source ENP Newswire